DKN-01 Demonstrates Immune Modulatory Activity and Robust Efficacy in Colorectal Cancer Models

Michael S Haas[1], Michael H Kagey[1], Walter Newman[1], James B Rottman[2], Milad Moloudizargari[3], Ajay Goel[3], Cynthia A Sirard[1], Jason Baum[1]

[1]Leap Therapeutics, Cambridge, MA; [2]Athenaeum Pathology Consulting, LLC, Sudbury, MA; [3]Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Poster # 1141

BACKGROUND

DKK1

- DKK1 is a secreted protein that plays a modulatory role in Wnt/β-catenin and PI3K/Akt signaling pathways.[1]
- DKK1 promotes tumor growth and contributes to an immunosuppressive tumor microenvironment.[1]
- DKN-01 is a targeted anti-DKK1 mAb that has demonstrated improved clinical outcomes in gastric and gastroesophageal junction adenocarcinoma patients.[2]

DKN-01 Mechanism of Action



Colorectal Cancer (CRC)

- CRC characterized by hyperactivation of the Wnt pathway, often believed to be the initiating and driving event.
- Adenomatous polyposis coli (APC) is the most frequently mutated gene in CRC (~80%) resulting in β-catenin stabilization and subsequent increased expression of DKK1.[3]
- DKK1 has been shown to be associated with resistance to 5-Fluorouracil (5FU), commonly used to treat metastatic CRC.[4]
- Anti-PD-1 therapies have not shown efficacy in microsatellite stable (MSS) CRC.[5] DKN-01 has demonstrated synergy with anti-PD-1 therapies in other indications.[2]

METHODS

Animal Models

- For the xenograft models, athymic nude mice were inoculated subcutaneously (SC) with either parental or 5FU-resistant colon carcinoma cell lines. Once tumors reached 50 mm^3, dosing was initiated with either Isotype control (IgG4; 5 mg/kg, BIW, IP), DKN-01 (5 mg/kg, BIW, IP), 5FU (30 mg/kg, Q2D, IP), or the combination.
- For the CT26 syngeneic model, BALB/c mice were inoculated SC with CT26 murine colon carcinoma cells. Once tumors reached 50 mm^3, dosing initiated with either Isotype control (IgG2a; 10 mg/kg, BIW, IP), a murinized version of DKN-01 (mDKN-01; 10 mg/kg, BIW, IP), anti-PD-1 (10 mg/kg, Q4D, IP), or the combination. Tumors were harvested 14 days post-treatment and both IHC and bulk RNAseq analyses were performed on each tumor.

Histology

- Formalin fixed paraffin embedded (FFPE) mouse tumor sections were prepared and stained via IHC. The relative amount of tumor PD-L1, CD3 and CD8 immunoreactivity was estimated in each section by measuring the percentage of the tumor area occupied by brown pixels, using the QuPath "Create Thresholder" function.

RESULTS

DKN-01 Has Activity in Multiple Xenografts Models Including Those That Are Resistant to 5FU

- DKN-01 has single agent efficacy in CRC xenograft models including HCT-116 and SW480.
- Additive activity was seen with 5FU in both models.
- 5FU resistant cell lines were created from both HCT-116 and SW480 cell lines, reflective of a second line CRC setting.[4]
- In the 5FU-resistant models (right panels), DKN-01 demonstrated significant inhibition of tumor growth.



mDKN-01 Has Monotherapy Activity Alone and in Combination with Anti-PD-1 in a Syngeneic CT26 Model

- mDKN-01 also has significant single agent efficacy in the MSS stable CRC syngeneic CT26 model.
- Additive activity was seen with anti-PD-1 with both mDKN-01 and combination treatment leading to tumor regression.



Treatment with mDKN-01 Alone and with Anti-PD-1 Increases PD-L1$^+$ Immunoreactivity in CT26 Tumors



Treatment with mDKN-01 Alone and with Anti-PD-1 Results in Increased T-Cell Infiltration in CT26 Tumors



- **Isotype control (IgG2a)** and **anti-PD-1** treated animals show minimal regions of tumor necrosis, widely scattered CD3$^+$ and CD8$^+$ T cells throughout the tumor and minimal presence in adjacent connective tissue.
- **mDKN-01** and **mDKN-01+ anti-PD-1** treated animals have substantial tumor necrosis, robust infiltration of CD3$^+$ and CD8$^+$ T cells along the periphery of the necrotic tumor and adjacent connective tissue.



Bulk RNAseq Analysis on CT26 Tumors

- Preliminary differential gene expression analysis comparing mDKN-01 vs Isotype control treated tumors reveal significant upregulation in cytotoxic and pro-inflammatory gene signatures.



CONCLUSIONS

- DKN-01 shows additive activity with 5FU and can overcome 5FU-resistance in two xenograft models, resulting in tumor regressions.
- 5FU-resistant models are reflective of a second-line CRC population currently being recruited in the DeFianCe study (NCT05480306).
- Treatment with mDKN-01 or in combination with anti-PD-1 results in tumor regression in a CT26 syngeneic model.
- mDKN-01 treatment increases PD-L1 immunoreactivity in a CRC syngeneic CT26 model.
- mDKN-01 used alone or in combination with anti-PD-1 promoted substantial CT26 tumor necrosis which was associated with a robust immune cell infiltrate and possible emergence of tertiary lymphoid structures in the peritumoral stroma.
- The CT26 tumor immune infiltrate observed in mDKN-01 / anti-PD-1 treated animals contains a substantial number of CD3$^+$ and CD8$^+$ cells, implying the presence of an adaptive immune response to tumor antigen.
- Initial bulk RNAseq analysis reveal mDKN-01 monotherapy significantly increases genes responsible for T cell activation, cytotoxic activity and TLS formation.

References: 1. Kagey MH, He X. *Br J Pharmacology*. 2017;174:4637–4650. 2. Klempner SJ, et al. *Mol Cancer Ther*. 2021;11:2240-2249. 3. Fearon ER. *Annu. Rev. Pathol. Mech. Dis.* 2011;6:479–507. 4. Zhao Y, et al. *Carcinogenesis*. 2021;42:814-825. 5. Ganesh K, et al. *Nat Rev Gastroenterol Hepatol*. 2019;16:361–375.

Acknowledgements: Poster design and creation by Laurie LaRusso, MS, ELS, Chestnut Medical Communications. Bulk RNAseq analysis was performed by Abbe Clark, PhD, Diamond Age Data Science.

Presented at Society for Immunotherapy of Cancer 37th Annual Meeting, November 8-12, 2022, Boston , MA